Loading…
No business profile yet.
Size Steminent Biotherapeutics (7729.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $458M, the 474th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$187.50 on 6 Nov 2026.
Performance Over six months the shares gained 139.2%, against -7.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 20 in its peer set.
Capital Return on invested capital runs 22.8 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$0 | NT$0 | NT$0 | NT$941,000 | NT$636,000 |
| Revenue growth | — | — | -100% | +48% | — |
| Gross profit | -NT$31.8M | -NT$30.9M | -NT$16.4M | -NT$12.7M | -NT$18.3M |
| EBITDA | -NT$177M | -NT$143M | -NT$146M | -NT$119M | -NT$88.8M |
| Net income | -NT$204M | -NT$174M | -NT$159M | -NT$129M | -NT$85.5M |
| Free cash flow | -NT$179M | -NT$140M | -NT$227M | -NT$142M | -NT$71.5M |
| Capital expenditure | NT$5.12M | NT$7.76M | NT$88.4M | NT$27.7M | NT$2.51M |
| Total debt | n/a | NT$77.4M | NT$63.8M | NT$75.4M | NT$55.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7729.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.0% | -13.9% | 10th highest of 21 |
| 6-month return | +139.2% | -7.3% | highest of 20 |
| Distance from 52-week high | -21.9% | -35.3% | 3rd highest of 21 |
| ROIC minus cost of capital | -22.8 pp | -9.3 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | 12.1× | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | 22.4× | 31.8% | -3.3% |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | 11.4× | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | 258.1× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 2.3× | 18.2% | +7.3% |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 18.0× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 2.5× | -14.9% | -36.1% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | 5.2× | 6.0% | -62.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | 12.1× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | 5.9× | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | 8,168.1× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 5.2× | 15.2% | +0.5% |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |